Go Pro
NASDAQ:LNAI

Lunai Bioworks Q2 2026 Earnings Report

Lunai Bioworks logo
$2.40 +0.20 (+9.09%)
As of 04:00 PM Eastern

Lunai Bioworks EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lunai Bioworks Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lunai Bioworks Announcement Details

Quarter
Q2 2026
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Lunai Bioworks Earnings Headlines

Lunai Bioworks Inc LNAI
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel
See More Lunai Bioworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lunai Bioworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lunai Bioworks and other key companies, straight to your email.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

View Lunai Bioworks Profile